Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

cTIV

Vaccine · Immune activation, directed at influenza virus hemagglutinin · developed by Novartis Vaccines

Phase 2 Most advanced trial (none active)
1 Registered trials

What is cTIV?

cTIV is an influenza vaccine administered by intramuscular injection. It is studied for prevention of influenza infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
influenza virus hemagglutinin (antigen)
Mechanism
Immune activation, directed at influenza virus hemagglutinin
Therapy area
Infectious disease
Developer
Novartis Vaccines
In trials of
NVAX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01561768 Phase 2 Influenza Completed NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.